摘要
目的:探究冠心病心力衰竭患者给予美托洛尔与曲美他嗪联合治疗的临床效果。方法:将2018年2月-2019年2月在房县中医院治疗76例冠心病心力衰竭患者作为探究对象,随机分为两组,每组38例,对照组予以常规治疗方案,观察组在此基础上给予美托洛尔联合曲美他嗪,将两组临床疗效和心脏功能对比。结果:观察组患者临床总有效97.4%(37/38)比对照组81.6%(31/38)高,差异有统计学意义(P<0.05);且观察组左心室舒张末内径(Left Ventricular End-diastolic Dimension,LVEDD)(50.3±3.0)mm、左室收缩末期内径(Left Ventricular End Systolic Diameter,LVESD)评分(35.2±2.2)mm低于对照组,差异具统计学意义(P<0.05)。结论:美托洛尔与曲美他嗪联合治疗冠心病心力衰竭效果显著,有效提升患者的心脏功能,值得在临床中进行推广。
Objective:To investigate the clinical effect of combination therapy of metoprolol and trimetazidine in patients with coronary heart disease with heart failure.Methods:From February 2018 to February 2019,76 patients with coronary heart disease with heart failure treated in our hospital were randomly divided into two groups,with 38 in each group.The control group received routine treatment.The observation group received metoprolol combined with trimetazidine.The clinical efficacy and cardiac function of the two groups were compared.Results:The total clinical effective rate was 97.4%(37/38)in the observation group,compared with 81.6%(31/38)in the control group,the difference was statistically significant(P<0.05).The observation group LVEDD(50.3±3.0)mm and LVESD score(35.2±2.2)mm were lower than those of the control group.The difference was statistically significant(P<0.05).Conclusion:Metoprolol combined with trimetazidine is effective in the treatment of coronary heart disease with heart failure,and it can effectively improve the heart function of patients,which is worthy of promotion in the clinic.
出处
《中医临床研究》
2020年第6期66-67,共2页
Clinical Journal Of Chinese Medicine
关键词
冠心病
心力衰竭
美托洛尔
曲美他嗪
临床效果
Coronary heart disease
Heart failure
Metoprolol
Trimetazidine
Clinical effect
